Eligibility
Any Age
All Sexes
What conditions do you have?
Select
Study Summary
This trial will compare nivolumab + relatlimab to nivolumab alone to see if the combo is more effective in treating melanoma.
Treatment Effectiveness
Effectiveness Progress
This is further along than 85% of similar trials
Study Objectives
1 Primary · 17 Secondary · Reporting Duration: Until second recurrence, up to 5 years
Day 135
Incidence of immune-mediated AEs (IMAEs)
Severity of IMAEs
Day 30
Incidence of AEs leading to discontinuation (DC)
Incidence of Adverse Events (AEs)
Incidence of Serious Adverse Events (SAEs)
Incidence of clinically significant changes in clinical laboratory values: Chemistry tests
Incidence of clinically significant changes in clinical laboratory values: Hematology tests
Incidence of deaths
Incidence of drug related AEs
Severity of AEs
Severity of AEs leading to DC
Severity of SAEs
Severity of drug related AEs
Month 96
Overall Survival (OS)
Month 96
Distant Metastasis-Free Survival (DMFS) time per Investigator assessment
Year 5
Duration of Treatment on next line therapies
Month 59
Recurrence-Free Survival (RFS) time per Investigator assessment
Year 5
Progression-Free Survival 2 (PFS2)
Trial Safety
Safety Progress
This is further along than 85% of similar trials
Trial Design
3 Treatment Groups
Arm B: Nivolumab
1 of 3
Arm A: Nivolumab Plus Relatlimab
1 of 3
Arm A: Relatlimab + Nivolumab
1 of 3
Experimental Treatment
1050 Total Participants · 3 Treatment Groups
Primary Treatment: Nivolumab + Relatlimab Fixed Dose Combination · No Placebo Group · Phase 3
Arm B: Nivolumab
Biological
Experimental Group · 1 Intervention: Nivolumab · Intervention Types: BiologicalArm A: Nivolumab Plus Relatlimab
Biological
Experimental Group · 1 Intervention: Nivolumab + Relatlimab Fixed Dose Combination · Intervention Types: BiologicalArm A: Relatlimab + NivolumabExperimental Group · 3 Interventions: Relatlimab + Nivolumab Fixed Dose Combination, Relatlimab, Nivolumab · Intervention Types: Biological, Biological, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Relatlimab
Not yet FDA approved
Nivolumab
FDA approved
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: until second recurrence, up to 5 years
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,481 Previous Clinical Trials
3,918,542 Total Patients Enrolled
174 Trials studying Melanoma
57,145 Patients Enrolled for Melanoma
Eligibility Criteria
Age Any Age · All Participants · 5 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have a melanoma that is surgically resected (free of disease) with negative margins.
You are eligible for the study if you have complete resection of your tumor within 90 days prior to randomization.
You must have disease-free status documented by a complete physical examination within 14 days prior to randomization and imaging studies within 35 days prior to randomization.
Participants ≥ 18 years of age must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
What state do they live in?
| Texas | 50.0% |
| Oregon | 50.0% |
How old are they?
| 18 - 65 | 50.0% |
| 65+ | 50.0% |
What site did they apply to?
| Local Institution | 50.0% |
| University of Texas MD Anderson Cancer Center-Melanoma Medical Oncology | 50.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments